Camp4 Therapeutics Financial Results
CAMP4 Therapeutics reported third quarter 2026 financial results, ending the period with $124.5 million in cash and cash equivalents. The company received regulatory clearances in the UK and EU to expand its Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder and remains on track to dose the first patient by year-end 2026. Management expects its current cash runway to fund operations through the end of 2028.
“The third quarter was one of continued execution for CAMP4. With regulatory clearances now in place in Australia, Argentina, the United Kingdom, and the European Union, we have launched our first-in-human ASCEND Phase 1/2 clinical trial of CMP-002 in patients with SYNGAP1-related disorder.”
Josh Mandel-Brehm, President and Chief Executive Officer
“There are no approved disease-modifying treatments for SYNGAP1, and we are committed to rapidly advancing the development of CMP-002 globally in the hopes of offering SYNGAP1 patients and families a potentially transformative solution that could one day dramatically improve their lives.”
Josh Mandel-Brehm, President and Chief Executive Officer